Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06101706
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2023-10-16
Brief Title:
Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients
Sponsor:
Centre Hospitalier Henri Duffaut - Avignon
Organization:
Centre Hospitalier Henri Duffaut - Avignon
Study Overview
Official Title:
Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RPso-Fatigue
Brief Summary:
Psoriatic arthritis is characterized with pain swelling and joint stiffness These are inflammatory reactions against tendons ligaments and joints associated with fatigue In France almost 93000 people are affected by psoriatic arthritis and the main symptoms appear between 30 and 50 years old Psoriatic arthritis may be due to a genetic predisposition involving the HLA B27 gene or to environmental factors such as stress physical or psychological trauma or infection Obesity type 2 diabetes and hypertension can also be factors associated with the onset of psoriatic arthritis
Cutaneous psoriasis is a non-contagious chronic inflammatory skin disease where the skin renews itself at an abnormally rapid rate In France between 2 and 3 million people are affected by cutaneous psoriasis approximately 60000 new cases every year The disease begin in adolescence or young adulthood There are multiples forms of cutaneous psoriasis plaque guttate pustular erythrodermic inverse facial scalp nail and mucous membranes The main symptom is the appearance of thick red patches of varying size covered with white dead skin These lesions are most often found on the hands elbows knees lower back face or scalp There is little to no itching During periods of remission lesions can disappear completely or partially then reappear during a new attack called a flare-up A familial genetic predisposition is present in 13 of psoriasis patients Other immune and environmental factors such as medication irritations sun exposure or psychological state can influence psoriasis flare-ups Psoriasis has no serious health consequences but it can be aesthetically unpleasant affect relationships and psychological well-being
Fatigue is a common symptom in psoriatic arthritis patients and can significantly affect quality of life and work capacity Fatigue which affects over 50 of psoriatic arthritis patients is a major component of the diseases impact Fatigue in psoriatic arthritis is a much-discussed topic in the current scientific literature Although less well documented patients with cutaneous psoriasis also experience fatigue Several clinical trials show that once the disease has been treated fatigue tends to diminish but in some cases the treatment itself may play a role in the vicious fatigue circle The risk of suffering other skin manifestations despite being under treatment can often be misunderstood by the patient leading to increased depression and fatigue Overall treatments are more likely to play an important role in the variability of fatigue Ultimately fatigue is a multifactorial symptom that can be linked either to the disease itself or to the therapies used It therefore appears to be the most difficult symptom to treat with commercially available therapies
As fatigue is a major symptom of psoriatic arthritis and cutaneous psoriasis it is essential to know how the therapies offered influence this symptom and to study whether certain therapies are more likely to increase it despite their efficacy on joint and skin symptoms It is also relevant to determine whether fatigue is correlated with disease severity duration and even more so with the therapy used to better understand the psychological impact of patients with psoriatic arthritis or cutaneous psoriasis
Cutaneous psoriasis is a non-contagious chronic inflammatory skin disease where the skin renews itself at an abnormally rapid rate In France between 2 and 3 million people are affected by cutaneous psoriasis approximately 60000 new cases every year The disease begin in adolescence or young adulthood There are multiples forms of cutaneous psoriasis plaque guttate pustular erythrodermic inverse facial scalp nail and mucous membranes The main symptom is the appearance of thick red patches of varying size covered with white dead skin These lesions are most often found on the hands elbows knees lower back face or scalp There is little to no itching During periods of remission lesions can disappear completely or partially then reappear during a new attack called a flare-up A familial genetic predisposition is present in 13 of psoriasis patients Other immune and environmental factors such as medication irritations sun exposure or psychological state can influence psoriasis flare-ups Psoriasis has no serious health consequences but it can be aesthetically unpleasant affect relationships and psychological well-being
Fatigue is a common symptom in psoriatic arthritis patients and can significantly affect quality of life and work capacity Fatigue which affects over 50 of psoriatic arthritis patients is a major component of the diseases impact Fatigue in psoriatic arthritis is a much-discussed topic in the current scientific literature Although less well documented patients with cutaneous psoriasis also experience fatigue Several clinical trials show that once the disease has been treated fatigue tends to diminish but in some cases the treatment itself may play a role in the vicious fatigue circle The risk of suffering other skin manifestations despite being under treatment can often be misunderstood by the patient leading to increased depression and fatigue Overall treatments are more likely to play an important role in the variability of fatigue Ultimately fatigue is a multifactorial symptom that can be linked either to the disease itself or to the therapies used It therefore appears to be the most difficult symptom to treat with commercially available therapies
As fatigue is a major symptom of psoriatic arthritis and cutaneous psoriasis it is essential to know how the therapies offered influence this symptom and to study whether certain therapies are more likely to increase it despite their efficacy on joint and skin symptoms It is also relevant to determine whether fatigue is correlated with disease severity duration and even more so with the therapy used to better understand the psychological impact of patients with psoriatic arthritis or cutaneous psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None